Business Context and Reporting Period
This Form 6-K, filed on May 26, 2004, by Prana Biotechnology Limited (ASX: PBT), discloses the Half Yearly Financial Report for the period ended December 31, 2003, and the results of the Annual General Meeting held on December 17, 2003. Prana is an Australian biotechnology company focused on developing Metal Protein Attenuating Compounds (MPACs) for neurodegenerative diseases, primarily Alzheimer's disease.
Key Financial Metrics
| Metric | Half Year Ended Dec 31, 2003 | Half Year Ended Dec 31, 2002 |
|---|---|---|
| Revenue | $1,123,587 | $526,700 |
| Net Loss | $(4,037,914) | $(3,138,115) |
| Operating Cash Flow | $(2,533,733) | $(2,199,891) |
| Cash and Cash Equivalents (Ending) | $5,620,156 | $1,446,025 |
| Net Assets | $16,572,843 | $15,823,703 |
| Net Tangible Asset Backing | 6.17 cents | 4.89 cents |
| Shares on Issue | 73,485,924 | 66,187,303 |
Debt and Liquidity: The company reported total liabilities of $1,687,174, consisting primarily of current payables ($1,631,520). There were no long-term borrowings disclosed. Liquidity improved significantly due to a capital raise, with cash assets increasing by approximately $2.19 million during the period.
Material Changes
- Revenue Growth: Revenue from ordinary activities increased by 113.33% to $1.12 million, driven largely by government grants (including $787,500 from Neuroscience Victoria and $65,746 from AusIndustry).
- Increased Loss: The net loss widened by 28.66% to $4.04 million. This was primarily due to a significant increase in Research and Development expenses, which rose from $1.06 million to $2.62 million.
- Capital Structure: The company completed a private placement in September 2003, issuing approximately 7.15 million shares at $0.70 each to raise $5 million. This increased contributed equity from $16.74 million to $21.53 million.
- Asset Base: Intangible assets remained stable at approximately $12 million, while cash reserves more than tripled compared to the prior period.
Outlook, Management Commentary, and Risks
Scientific Milestones: Management highlighted the publication of successful Phase-2 clinical trial results for PBT-1 in the "Archives of Neurology." A new lead candidate, PBT-2, has been identified and is scheduled to enter Phase-1 clinical trials in the third quarter of 2004. Additionally, a collaboration was formed with Panvax Limited and the University of Melbourne to develop an Alzheimer's vaccine.
Going Concern: Despite a net loss and negative operating cash flow, directors assert the going concern basis is appropriate. This view is supported by sufficient cash reserves to meet obligations through June 2004, the existence of 20 million share options (exercise price $0.50) expected to be exercised upon meeting milestones, and a history of successful capital raising.
Risks and Contingencies: The filing notes no change in contingent liabilities. The primary risk remains the company's reliance on continued capital raising and the successful execution of clinical trials to achieve profitability.
Investor Verification Checklist
- Verify the status and regulatory approval for the planned Phase-1 clinical trials of PBT-2 scheduled for Q3 2004.
- Confirm the exercise status of the 20 million share options outstanding and their potential dilution impact.
- Monitor the burn rate of the $5.6 million cash balance against the projected operating expenses for the full year 2004.
- Review the terms of the collaboration with Panvax Limited and the University of Melbourne regarding the Alzheimer's vaccine.
- Assess the sustainability of government grant revenue, which constituted a significant portion of total revenue.